1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Persistent Epithelial Defect - Epidemiology forecast- 2030

Persistent Epithelial Defect - Epidemiology forecast- 2030

  • August 2021
  • 80 pages
  • ID: 5921866
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Persistent Epithelial Defect (PED)–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Persistent Epithelial Defect (PED) Disease Understanding
Persistent Corneal Epithelial Defects, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10–14 days after a corneal injury, even with standard supportive treatment. The cornea is the transparent, outermost layer of the eye that uniformly refracts the majority of the light that enters the eye onto the lens and is essential for ideal vision. The corneal surface is composed of five or six layers of epithelial cells.

Healthy corneal epithelium is integral in preventing corneal infections and protecting the damage to the deeper corneal tissue. It is several layers thick and acts as a barrier via tightly linked cells through hemidesmosomes and gap junctions. The surface integrity alongside the corneal transparency is very important in maintaining the corneal refractive role in vision.

The high turnover of the epithelial cells helps heal minor corneal abrasions and acute epithelial defects uneventfully within 7–14 days. The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Disruptions in this protective layer can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and decreased visual acuity. PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7–14 days’ time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.

Persistent Epithelial Defect (PED) Epidemiology
The Persistent Epithelial Defect (PED) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Defect (PED) epidemiology segmented as the Total Incident Cases of Persistent Epithelial Defect (PED), Gender-specific incidence of Persistent Epithelial Defect (PED), Etiology-specific incidence of Persistent Epithelial Defect (PED). The report includes the Incident scenario of Persistent Epithelial Defect (PED) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Persistent Epithelial Defect (PED) Epidemiology
The epidemiology segment also provides the Persistent Epithelial Defect (PED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident population of Persistent Epithelial Defect (PED) Associated in 7MM countries was estimated to be 241,452 cases in 2020 and expected to increase for the study period, i.e., 2018–2030.
• As per the estimates, United States has the highest incident population of Persistent Epithelial Defect (PED) in 7MM.
Among the EU5 countries, Germany had the highest incident population of Persistent Epithelial Defect (PED). On the other hand, Spain had the lowest number of cases, 14,547 cases in 2020.

Scope of the Report
• Persistent Epithelial Defect (PED) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Persistent Epithelial Defect (PED) Epidemiology Report and Model provide an overview of the risk factors and global trends of Persistent Epithelial Defect (PED) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Persistent Epithelial Defect (PED) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Persistent Epithelial Defect (PED)
• The report provides the segmentation of the Persistent Epithelial Defect (PED) epidemiology by incident Cases of Persistent Epithelial Defect (PED) in 7MM
• The report provides the segmentation of the Persistent Epithelial Defect (PED) epidemiology by incidence of Persistent Epithelial Defect (PED), Total Incident Cases of Persistent Epithelial Defect (PED), Severity-specific incidence of Persistent Epithelial Defect (PED), Incident Cases of Persistent Epithelial Defect (PED) Based on risk Factors in 7MM

Report Highlights

• 10-year Forecast of Persistent Epithelial Defect (PED) epidemiology
• 7MM Coverage
• Total Incident Cases of Persistent Epithelial Defect (PED)
• Severity-specific incidence of Persistent Epithelial Defect (PED)
• Incident Cases of Persistent Epithelial Defect (PED) Based on risk Factors

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Persistent Epithelial Defect (PED)?
• What are the key findings of Persistent Epithelial Defect (PED) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2030)?
• What would be the total number of patients with Persistent Epithelial Defect (PED) across the 7MM during the forecast period (2021–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2030)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2030)?
• What are the disease risk, burden, and unmet needs of Persistent Epithelial Defect (PED)?
• What are the currently available treatments for Persistent Epithelial Defect (PED)?

Reasons to buy
The Persistent Epithelial Defect (PED) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Persistent Epithelial Defect (PED) market
• Quantify patient populations in the global Persistent Epithelial Defect (PED) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Persistent Epithelial Defect (PED) therapeutics in each of the markets covered
• Understand the magnitude of Persistent Epithelial Defect (PED) population by its incident cases
• Understand the magnitude of Persistent Epithelial Defect (PED) population by its risk factors cases
• The Persistent Epithelial Defect (PED) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Persistent Epithelial Defect (PED) Epidemiology Model developed is easy to navigate, interactive with dashboPED, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Severe Sepsis and Septic Shock - Epidemiology Forecast to 2030

  • $ 3995
  • August 2021
  • 52 pages

Severe Sepsis and Septic Shock - Epidemiology Forecast to 2030 Summary Severe sepsis and septic shock are life-threatening conditions with a very high mortality rate.Severe sepsis is defined as life-threatening ...

  • United States
  • United Kingdom
  • Blood Disease
  • Epidemiology
  • Industry analysis
  • Mortality Rate
  • Health Provider Density

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on